Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits

Experimental Neurology

Volumn 185, Issue 1, 2004, Pages 154-159

  Lapchak, Paul A ^a,b,c   Araujo, Dalia M ^b   Zivin, Justin A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Embolism; Neuroprotection; Reperfusion; TNK; tPA

Indexed keywords

ALTEPLASE; TENECTEPLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CATHETER; ARTICLE; ARTIFICIAL EMBOLISM; BEHAVIOR; BEHAVIORAL SCIENCE; BIOLOGICAL MODEL; BLOOD CLOT LYSIS; BLOOD CLOTTING; BRAIN HEMORRHAGE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMBOLIC STROKE; EMBOLISM; INJECTION; MALE; MIDDLE CEREBRAL ARTERY; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SCORING SYSTEM; STROKE;

EID: 0347624526     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.09.009     Document Type: Article

References (31)

1. Angeja B.G., Alexander J.H., Chin R., Li X., Barron H.V., Armstrong P.W., Granger C.B., Van de Werf F., Gibson C.M. Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. Am. J. Cardiol. 88:2001;1240-1245.
2. Asahi M., Asahi K., Wang X., Lo E.H. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 20:2000;452-457.
3. Cannon C.P., Weintraub W.S., Demopoulos L.A., Robertson D.H., Gormley G.J., Braunwald E. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 trial. Treat Angina with Aggrastat and determine cost of therapy with an invasive or conservative strategy. Thrombolysis in myocardial infarction. Am. J. Cardiol. 82:1998;731-736.
4. Chapman D.F., Lyden P., Lapchak P.A., Nunez S., Thibodeaux H., Zivin J. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke. 32:2001;748-752.
5. Clark R.K., Lee E.V., White R.F., Jonak Z.L., Feuerstein G.Z., Barone F.C. Reperfusion following focal stroke hastens inflammation and resolution of ischemic injured tissue. Brain Res. Bull. 35:1994;387-392.
6. Davydov L., Cheng J.W. Tenecteplase: a review. Clin. Ther. 23:2001;982-997. discussion 981.
7. Dundar Y., Hill R., Dickson R., Walley T. Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. QJM. 96:2003;103-113.
8. Hacke W. Desmoteplase in acute ischemic stroke (DIAS). Stroke. 2003;. CTP14.
9. Jean W.C., Spellman S.R., Nussbaum E.S., Low W.C. Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery. 43:1998;1382-1396. discussion 1396-1387.
10. Keyt B.A., Paoni N.F., Refino C.J., Berleau L., Nguyen H., Chow A., Lai J., Pena L., Pater C., Ogez J.et al. A faster-acting and more potent form of tissue plasminogen activator. Proc. Natl. Acad. Sci. U. S. A. 91:1994;3670-3674.
11. Lapchak P.A. Development of thrombolytic therapy for stroke: a perspective. Expert Opin. Investig. Drugs. 11:2002;1623-1632.
12. Lapchak P.A. NXY-059 monograph. Curr. Opin. Invest. Drugs. 3:2002;1758-1762.
13. Lapchak P.A., Araujo D.M. Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents. CNS Drugs. 15:2001;819-829.
14. Lapchak P.A., Araujo D.M. Spin trap agents: implications to treat acute stroke. Drug News and Perspect. 15:2002;220-225.
15. Lapchak P.A., Zivin J.A. Ebselen, a seleno-organic antioxidant, is neuroprotective following embolic strokes in rabbits: synergism with low dose tissue plasminogen activator. Stroke. 34:2003;2013-2018.
16. Lapchak P.A., Chapman D.F., Zivin J.A. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 31:2000;3034-3040.
17. Lapchak P.A., Araujo D.M., Pakola S., Song D., Wei J., Zivin J.A. Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke. 33:2002;2279-2284.
18. Lapchak P.A., Araujo D.M., Song D., Wei J., Zivin J.A. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3- disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke. 33:2002;1411-1415.
19. Lapchak P.A., Araujo D.M., Song D., Zivin J.A. The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke. Stroke. 33:2002;147-152.
20. Lyden P., Jacoby M., Schim J., Albers G., Mazzeo P., Ashwood T., Nordlund A., Odergren T. The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results. Neurology. 57:2001;1199-1205.
21. Morris D.C., Zhang L., Zhang Z.G., Lu M., Berens K.L., Brown P.M., Chopp M. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke. 32:2001;2635-2640.
22. Rosenberg G.A. Ischemic brain edema. Prog. Cardiovasc. Dis. 42:1999;209-216.
23. Siesjo B.K., Siesjo P. Mechanisms of secondary brain injury. Eur. J. Anaesthesiol. 13:1996;247-268.
24. Smalling R.W. Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am. J. Cardiol. 78:1996;2-7.
25. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333:1995;1581-1587.
26. Van de Werf F., Barron H.V., Armstrong P.W., Granger C.B., Berioli S., Barbash G., Pehrsson K., Verheugt F.W., Meyer J., Betriu A., Califf R.M., Li X., Fox N.L. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur. Heart J. 22:2001;2253-2261.
27. Zhang R.L., Zhang L., Jiang Q., Zhang Z.G., Goussev A., Chopp M. Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat. Brain Res. 878:2000;64-71.
28. Zhang Z., Zhang L., Yepes M., Jiang Q., Li Q., Arniego P., Coleman T.A., Lawrence D.A., Chopp M. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation. 106:2002;740-745.
29. Zivin J.A. Thrombolytic stroke therapy: past, present, and future. Neurology. 53:1999;14-19.
30. Zivin J.A., Waud D.R. Quantal bioassay and stroke. Stroke. 23:1992;767-773.
31. Zivin J.A., Lyden P.D., DeGirolami U., Kochhar A., Mazzarella V., Hemenway C.C., Johnston P. Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke. Arch. Neurol. 45:1988;387-391.